{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T01:40:55Z","timestamp":1785289255745,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Herzzentrum M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The expanding use of bioprosthetic aortic valve replacements has raised concerns regarding the long-term durability of bioprosthetic valve prostheses. While lipoprotein(a) [Lp(a)] is implicated in the pathogenesis of native aortic valve stenosis, its impact on bioprosthetic valve degeneration leading to reintervention remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between Lp(a) levels and structural degeneration of aortic bioprosthetic valves in patients undergoing secondary aortic valve procedure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 389 patients with available Lp(a) values who underwent replacement of a degenerated aortic bioprosthetic valves between February 2001 and September 2024. Endpoint was the interval from initial surgical aortic valve replacement (SAVR) to the second aortic valve procedure either as transvascular or surgical replacement. Patients were stratified by Lp(a) levels into low (&lt;\u2009105\u00a0nmol\/L) and high (\u2265\u2009105\u00a0nmol\/L) Lp(a) groups. Associations between Lp(a) levels and time-to-reintervention were assessed using Kaplan\u2013Meier survival analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of an initial cohort of 909 patients, 389 met the inclusion criteria. Of these, 296 patients showed low and 93 high Lp(a) levels. Baseline characteristics were comparable between both groups. The median time from initial valve implantation to the second aortic valve intervention did not differ significantly by Lp(a) group. Kaplan\u2013Meier analysis demonstrated no significant association between elevated Lp(a) and time-to-reintervention (hazard ratio [HR] 0.81; 95% confidence interval [CI] 0.58 \u2013 1.13; p\u2009=\u20090.215).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this cohort of patients undergoing secondary aortic valve procedure, elevated Lp(a) levels were not associated with earlier need for reintervention. Unlike in native aortic stenosis, our findings do not support a clinically meaningful role for Lp(a) in bioprosthetic aortic valve degeneration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-026-02933-3","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:31:39Z","timestamp":1779085899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of lipoprotein(a) on the durability of aortic bioprosthetic valves"],"prefix":"10.1007","author":[{"given":"Finn","family":"Syryca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Krefting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Rheude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Patrick","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Holdenrieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector A.","family":"Alvarez-Covarrubias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"von Scheidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik B.","family":"Sager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"Schunkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Erlebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erion","family":"Xhepa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Ruge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Joner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Krane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Trenkwalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"16","key":"2933_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.125.043061","volume":"14","author":"H Li","year":"2025","unstructured":"Li H et al (2025) Advancements and perspectives in the bioprosthetic heart valve: A comprehensive review on biomaterial processing and emerging polymeric materials. J Am Heart Assoc 14(16):e043061","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"2933_CR2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jacc.2017.07.715","volume":"70","author":"T Rodriguez-Gabella","year":"2017","unstructured":"Rodriguez-Gabella T et al (2017) Aortic bioprosthetic valve durability: incidence, mechanisms, predictors, and management of surgical and transcatheter valve degeneration. J Am Coll Cardiol 70(8):1013\u20131028","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2933_CR3","doi-asserted-by":"publisher","first-page":"846","DOI":"10.4244\/EIJV15I10A160","volume":"15","author":"D Capodanno","year":"2019","unstructured":"Capodanno D, S\u00f8ndergaard L, Tamburino C (2019) Durability of transcatheter bioprosthetic aortic valves: the story so far. EuroIntervention 15(10):846\u2013849","journal-title":"EuroIntervention"},{"issue":"19","key":"2933_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018506","volume":"9","author":"AE Kostyunin","year":"2020","unstructured":"Kostyunin AE et al (2020) Degeneration of bioprosthetic heart valves: update 2020. J Am Heart Assoc 9(19):e018506","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"2933_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/jamacardio.2024.1882","volume":"9","author":"BJ Arsenault","year":"2024","unstructured":"Arsenault BJ et al (2024) Lipoprotein(a) and calcific aortic valve stenosis progression: A systematic review and meta-analysis. JAMA Cardiol 9(9):835\u2013842","journal-title":"JAMA Cardiol"},{"issue":"17","key":"2933_CR6","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","volume":"73","author":"KH Zheng","year":"2019","unstructured":"Zheng KH et al (2019) Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol 73(17):2150\u20132162","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2933_CR7","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1001\/jamacardio.2018.3798","volume":"3","author":"R Capoulade","year":"2018","unstructured":"Capoulade R et al (2018) Association of mild to moderate aortic valve stenosis progression with higher lipoprotein(a) and oxidized phospholipid levels: secondary analysis of a randomized clinical trial. JAMA Cardiol 3(12):1212\u20131217","journal-title":"JAMA Cardiol"},{"issue":"3","key":"2933_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","volume":"13","author":"DP Wilson","year":"2019","unstructured":"Wilson DP et al (2019) Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. a scientific statement from the National Lipid Association. J Clin Lipidol 13(3):374\u2013392","journal-title":"J Clin Lipidol"},{"issue":"3","key":"2933_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cjco.2019.03.004","volume":"1","author":"AA Despr\u00e9s","year":"2019","unstructured":"Despr\u00e9s AA et al (2019) Lipoprotein(a), oxidized phospholipids, and aortic valve microcalcification assessed by 18F-sodium fluoride positron emission tomography and computed tomography. CJC Open 1(3):131\u2013140","journal-title":"CJC Open"},{"key":"2933_CR10","unstructured":"Novartis (2024) A multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis\u00a0(NCT05646381)"},{"issue":"4","key":"2933_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1136\/heartjnl-2023-322987","volume":"110","author":"JM Farina","year":"2024","unstructured":"Farina JM et al (2024) Role of lipoprotein(a) concentrations in bioprosthetic aortic valve degeneration. Heart 110(4):299\u2013305","journal-title":"Heart"},{"issue":"3","key":"2933_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00392-024-02587-z","volume":"114","author":"J Bormann","year":"2025","unstructured":"Bormann J et al (2025) The influence of lipoprotein(a) on aortic valve calcification in patients undergoing transcatheter aortic valve replacement. Clin Res Cardiol 114(3):395\u2013404","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"2933_CR13","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/ehjci\/jeac274","volume":"24","author":"SB Botezatu","year":"2023","unstructured":"Botezatu SB et al (2023) Serum lipoprotein(a) and bioprosthetic aortic valve degeneration. Eur Heart J Cardiovasc Imaging 24(6):759\u2013767","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"6","key":"2933_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/MOL.0000000000000855","volume":"33","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG (2022) Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees. Curr Opin Lipidol 33(6):342\u2013352","journal-title":"Curr Opin Lipidol"},{"key":"2933_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11061661","author":"S Genovesi","year":"2023","unstructured":"Genovesi S et al (2023) Evidence and uncertainties on Lipoprotein(a) as a marker of cardiovascular health risk in children and adolescents. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11061661","journal-title":"Biomedicines"},{"issue":"5","key":"2933_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeae064","volume":"4","author":"T Harb","year":"2024","unstructured":"Harb T et al (2024) Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk. Eur Heart J Open 4(5):oeae064","journal-title":"Eur Heart J Open"},{"issue":"42","key":"2933_CR17","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F et al (2025) 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J 46(42):4359\u20134378","journal-title":"Eur Heart J"},{"issue":"39","key":"2933_CR18","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 43(39):3925\u20133946","journal-title":"Eur Heart J"},{"issue":"2","key":"2933_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1001\/jamacardio.2024.3738","volume":"10","author":"T Trenkwalder","year":"2025","unstructured":"Trenkwalder T et al (2025) Distinct genetic risk profile in aortic stenosis compared with coronary artery disease. JAMA Cardiol 10(2):145\u2013154","journal-title":"JAMA Cardiol"},{"issue":"2","key":"2933_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","volume":"71","author":"S Tsimikas","year":"2018","unstructured":"Tsimikas S et al (2018) NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol 71(2):177\u2013192","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2933_CR21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.115.016757","volume":"132","author":"R Bouchareb","year":"2015","unstructured":"Bouchareb R et al (2015) Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. Circulation 132(8):677\u2013690","journal-title":"Circulation"},{"issue":"2","key":"2933_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","volume":"121","author":"KL Chan","year":"2010","unstructured":"Chan KL et al (2010) Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 121(2):306\u2013314","journal-title":"Circulation"},{"key":"2933_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207434","author":"A Kostyunin","year":"2020","unstructured":"Kostyunin A et al (2020) Ultrastructural pathology of atherosclerosis, calcific aortic valve disease, and bioprosthetic heart valve degeneration: commonalities and differences. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21207434","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2933_CR24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1365-2362.2009.02132.x","volume":"39","author":"R Shetty","year":"2009","unstructured":"Shetty R et al (2009) Lipid-mediated inflammation and degeneration of bioprosthetic heart valves. Eur J Clin Invest 39(6):471\u2013480","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"2933_CR25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian A et al (2022) 2021 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J 43(7):561\u2013632","journal-title":"Eur Heart J"},{"issue":"3","key":"2933_CR26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S et al (2020) Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 382(3):244\u2013255","journal-title":"N Engl J Med"},{"issue":"10057","key":"2933_CR27","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney NJ et al (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388(10057):2239\u20132253","journal-title":"Lancet"},{"issue":"2","key":"2933_CR28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2015.08.021","volume":"242","author":"AH Nave","year":"2015","unstructured":"Nave AH et al (2015) Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis 242(2):496\u2013503","journal-title":"Atherosclerosis"},{"issue":"4","key":"2933_CR29","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"S Erqou","year":"2009","unstructured":"Erqou S et al (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302(4):412\u2013423","journal-title":"JAMA"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02933-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-02933-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02933-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:31:42Z","timestamp":1779085902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-02933-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":29,"alternative-id":["2933"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-02933-3","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest or competing interests relevant to the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}}]}}